Related Experiment Videos
GDMT Intensity at Hospital Discharge and Associated Clinical Outcomes in Heart Failure: A Systematic Review and
Sergio Alejandro Gómez-Ochoa1,2, Lyda Z Rojas3, Carlos A Corona-Arias4
1Heart Failure and Heart Transplant Clinic, Fundación Cardiovascular de Colombia, Floridablanca 681004, Colombia.
Insights
Guideline-directed medical therapy (GDMT) intensity at hospital discharge is linked to better heart failure (HF) outcomes. Higher GDMT intensity, especially quadruple therapy, shows a significant association with reduced mortality and HF hospitalizations.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Contemporary heart failure (HF) guidelines advocate for early initiation of four foundational drug classes in heart failure with reduced ejection fraction (HFrEF).
- Real-world prescription rates of guideline-directed medical therapy (GDMT) at hospital discharge are suboptimal.
- Limited comparative data exists on the impact of GDMT intensity at discharge on clinical outcomes.
Purpose of the Study:
- To explore the association between GDMT intensity prescribed at or before hospital discharge and clinical outcomes in HFrEF patients.
- To analyze real-world prescription patterns of GDMT in the SGLT2i era.
- To compare the effectiveness of different GDMT regimen intensities.
Main Methods:
- A systematic search of MEDLINE and EMBASE databases was conducted.
- A frequentist random-effects network meta-analysis was performed, grouping regimens into four intensity nodes (single/none, double, triple, quadruple).
- The primary outcome was the composite of all-cause mortality (ACM) and HF hospitalization (HFH), with secondary outcomes including HFH, ACM, and cardiovascular mortality. Confidence in estimates was rated using CINeMA.
Main Results:
- Twenty-seven studies involving 73,174 patients were included; quadruple therapy was prescribed in only 34% of SGLT2i-era cohorts.
- Higher GDMT intensity was associated with progressively lower event rates for the primary composite endpoint: double therapy (HR 0.76), triple therapy (HR 0.72), and quadruple therapy (HR 0.52).
- A consistent ordinal gradient was observed across outcomes, with quadruple therapy showing the best numerical ranking where estimable. Associations are not causal due to observational data.
Conclusions:
- Discharge GDMT intensity represents a significant opportunity to improve outcomes for patients with HF.
- Current prescription rates for intensive GDMT regimens remain low.
- Adequately powered randomized trials are necessary to establish the definitive incremental benefit of intensive GDMT and bridge the evidence-practice gap.
Abstract:
Background/Objectives: Contemporary heart failure (HF) guidelines recommend early initiation of four foundational drug classes in HFrEF. However, real-world prescription rates of guideline-directed medical therapy (GDMT) at discharge remain low, and comparative data in this setting is limited. We aimed to explore the association between GDMT intensity prescribed at or before hospital discharge and clinical outcomes. Methods: MEDLINE and EMBASE were searched through March 2026 (PROSPERO CRD420261352137). A frequentist random-effects network meta-analysis grouped regimens into four intensity nodes (single/none, double, triple, quadruple), with the primary analysis restricted to adjusted hazard ratios. The primary outcome was the composite of all-cause mortality (ACM) and HF hospitalization (HFH). Secondary outcomes were HFH alone, ACM, and cardiovascular mortality. Confidence was rated with CINeMA. Estimates are reported as associations, not treatment effects. Results: Twenty-seven studies (26 observational, 1 RCT; 73,174 patients) were included. Among SGLT2i-era cohorts, quadruple therapy was suboptimally prescribed (pooled 34%, range 11.6-55.2%). For the primary composite endpoint, more complete regimens were associated with progressively lower event rates versus single or no therapy (double: hazard ratio 0.76, 95% CI 0.68-0.84; triple: 0.72, 0.64-0.81; quadruple: 0.52, 0.36-0.75; τ2 = 0). A consistent ordinal gradient was seen across outcomes, with quadruple therapy ranking first numerically for every outcome in which it was estimable. The direction and ordering were preserved in a sensitivity analysis additionally incorporating risk ratios, on stratification by follow-up duration, and in an alternative network anchored to incomplete therapy. Because most evidence was observational, the magnitude of these associations should not be interpreted as a causal treatment effect and likely reflects residual confounding and selection bias. Conclusions: Discharge GDMT remains an important opportunity to improve outcomes in patients with HF. Adequately powered randomized trials are required to establish the incremental benefit of this approach and to close the gap between evidence and practice.
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations